article · npj Vaccines
Group A Streptococcus (GAS) remains a major global health challenge, causing over half a million deaths annually. Despite nearly a century of research, no licensed vaccine is currently available, due to antigenic diversity, complex host-pathogen interactions, risk of autoimmunity and lack of clear correlates of protection. This review discusses recent advances in GAS vaccine research, highlights key challenges and outlines criteria and emerging opportunities for antigen selection.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1038/s41541-026-01445-5
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
